Oncothyreon Inc. (NASDAQ: ONTY) is a rare stock for volume alerts. It showed clinical data relating to long-term communication with Stimuvax were presented at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung Cancer in San Francisco over the weekend. As of April 2009, 10 of the 16 unnatural patients were alive without grounds of disease progression and eight continued to obtain therapy with Stimuvax after 6.3 to 8.2 years. The remaining two experience patients discontinued Stimuvax therapy after 2.4 and 5.8 years and were without grounds of disease progression. Nine of the 10 experience patients had stage IIIb NSCLC upon entry to the trial, while digit had stage IV disease. Six of the 10 experience patients had a complete salutation to their first-line chemotherapy or chemo-radiation, while four patients had stable disease. The remaining six of the 16 patients discontinued Stimuvax after 2.0 to 5.1 years of communication as a result of disease progression and are deceased. A 8:23 AM EST we have seen nearly 100,000 shares trade hands versus an cipher daily volume of wrinkled 400,000 shares per day. Shares are up 13% at $5.25 after closing at $4.629 on Friday. -JON OGG
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment